Filing Details
- Accession Number:
- 0000914475-11-000012
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-03-02 17:06:21
- Reporting Period:
- 2011-02-28
- Filing Date:
- 2011-03-02
- Accepted Time:
- 2011-03-02 17:06:21
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 914475 | Neurocrine Biosciences Inc | NBIX | Biological Products, (No Disgnostic Substances) (2836) | 330525145 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1201096 | Charles Kevin Gorman | Neurocrine Biosciences, Inc. 12780 El Camino Real San Diego CA 92130 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2011-02-28 | 15,400 | $6.83 | 177,202 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Sale of 15,400 shares of common stock issued upon vesting of 41,667 restricted stock units on February 27, 2011 to cover payroll and withholding taxes, with the balance of the shares (26,267) maintained by the Reporting Person; the sale was affected by a broker pursuant to instructions set forth in a Rule 10b5-1 plan adopted by the Reporting Person and delivered to the broker on May 26, 2009.
- Represents a weighted average sales price per share. The prices actually received ranged from $6.58 to $7.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 158,540 non-derivative securites are held directly by Reporting Person; 14,662 non-derivative securities are held indirectly by the KCG Limited Liability Company.
Billionaire Hedge Funds
